慢性肾脏病患者的动脉与细胞炎症
研究对比14例无心血管疾病、糖尿病或炎症性疾病的CKD患者与14例对照者的18F-FDG PET/CT及单核细胞功能,发现CKD患者主动脉和颈动脉TBRmax显著升高,单核细胞趋化因子受体表达及跨内皮迁移能力增强,提示动脉壁炎症与单核细胞活性升高可能参与CKD相关心血管风险。
要点
- CKD患者主动脉TBRmax 3.14±0.70,高于对照2.12±0.27(P=0.001)。
- CKD患者颈动脉TBRmax 2.45±0.65,高于对照1.66±0.27(P<0.001)。
- CKD患者循环单核细胞趋化因子受体表达及跨内皮迁移能力增强。
核心结论
- CKD患者即使无明确动脉粥样硬化性疾病且传统危险因素较少,仍存在增高的动脉壁炎症,可能贡献于CKD相关心血管风险。
- 单核细胞活性同步升高,可能为减轻该炎症并提供预防CKD相关心血管疾病的新治疗靶点。
研究设计与样本
- 研究纳入14例CKD患者(平均±SD年龄59±5岁,平均±SD eGFR 37±12 ml/min per 1.73 m2)且无心血管疾病、糖尿病或炎症性疾病,以及14例对照者(平均年龄60±11岁,平均eGFR 86±16 ml/min per 1.73 m2)。
- 采用18F-氟脱氧葡萄糖(18F-FDG)正电子发射断层扫描计算机断层扫描(PET/CT)评估动脉壁摄取,并以流式细胞术表征循环单核细胞。
主要发现
- 与对照相比,CKD患者主动脉靶本底比(TBR)最大值升高:CKD 3.14±0.70 vs 对照2.12±0.27(P=0.001)。
- 与对照相比,CKD患者颈动脉TBR最大值升高:CKD 2.45±0.65 vs 对照1.66±0.27(P<0.001)。
- 流式细胞术显示CKD患者循环单核细胞趋化因子受体表达增加、跨内皮迁移能力增强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CKD associates with a 1.5- to 3.5-fold increased risk for cardiovascular disease. Both diseases are characterized by increased inflammation, and in patients with CKD, elevated C-reactive protein level predicts cardiovascular risk. In addition to systemic inflammation, local arterial inflammation, driven by monocyte-derived macrophages, predicts future cardiovascular events in the general population. We hypothesized that subjects with CKD have increased arterial and cellular inflammation, reflected by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography computed tomography (PET/CT) of the arterial wall and a migratory phenotype of monocytes. We assessed 18F-FDG uptake in the arterial wall in 14 patients with CKD (mean±SD age: 59±5 years, mean±SD eGFR: 37±12 ml/min per 1.73 m2) but without cardiovascular diseases, diabetes, or inflammatory conditions and in 14 control subjects (mean age: 60±11 years, mean eGFR: 86±16 ml/min per 1.73 m2). Compared with controls, patients with CKD showed increased arterial inflammation, quantified as target-to-background ratio (TBR) in the aorta (TBRmax: CKD, 3.14±0.70 versus control, 2.12±0.27; P=0.001) and the carotid arteries (TBRmax: CKD, 2.45±0.65 versus control, 1.66±0.27; P<0.001). Characterization of circulating monocytes using flow cytometry revealed increased chemokine receptor expression and enhanced transendothelial migration capacity in patients with CKD compared with controls. In conclusion, this increased arterial wall inflammation, observed in patients with CKD but without overt atherosclerotic disease and with few traditional risk factors, may contribute to the increased cardiovascular risk associated with CKD. The concomitant elevation of monocyte activity may provide novel therapeutic targets for attenuating this inflammation and thereby preventing CKD-associated cardiovascular disease.
引用
- Bernelot Moens SJ, Verweij SL, van der Valk FM, et al. Arterial and Cellular Inflammation in Patients with CKD. J Am Soc Nephrol. 2016. PMID: 27799487. doi:10.1681/ASN.2016030317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。